GlassScriptPhysician profile
Amin Gerious Mery
NPI 1225035363
$16,491.67
in general payments reported to CMS, 2019-2025
36 companies · $5,330 in 2025
The $5,330 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $3,206 · 2021: $760 · 2022: $1,423 · 2023: $1,045 · 2024: $3,236 · 2025: $5,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,089 · Food and Beverage: $4,366 · Education: $124 · Travel and Lodging: $32.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,088.62 |
| Food and Beverage | $4,365.99 |
| Education | $123.99 |
| Travel and Lodging | $32.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,220.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $3,149.43 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $2,292.00 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,746.03 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $839.95 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $806.70 | 2019-2025 | Nucala, Trelegy Ellipta |
| Alk-Abello, INC | $611.26 | 2019-2025 | Timothy, Standardized, Alternaria Tenuis, Standardized Mite D. Farinae |
| Amgen INC. | $480.61 | 2021-2025 | Tezspire |
| Mylan Specialty L.P. | $395.59 | 2020-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $312.11 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $237.96 | 2021-2024 | Xolair |
| Pfizer INC. | $191.12 | 2019-2022 | |
| Greer Laboratories, INC. | $155.16 | 2019-2025 | Oralair |
| Kaleo, INC. | $126.47 | 2019-2023 | Auvi-Q |
| Pharming Healthcare, INC. | $118.46 | 2020-2025 | Ruconest |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $110.93 | 2025 | Barrigel |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Abbvie INC. | $89.54 | 2022-2023 | |
| Optinose US, INC. | $64.58 | 2019 | |
| Ionis Pharmaceuticals, INC. | $46.92 | 2025 | Dawnzera |
| Shire North American Group INC | $34.92 | 2019 | |
| Inspire Medical Systems, INC. | $32.86 | 2025 | Inspire |
| Biocryst US Sales Co., LLC | $31.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $31.32 | 2021 | |
| Adma Biomanufacturing LLC | $30.62 | 2025 | |
| Viatris Specialty LLC | $30.04 | 2025 | Yupelri |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $25.75 | 2025 | Neffy |
| Csl Behring | $25.15 | 2025 | Hizentra |
| Cycle Pharmaceuticals INC | $24.00 | 2025 | Sajazir |
| Jubilant Hollisterstier LLC | $23.05 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.21 | 2021 | |
| Octapharma USA, INC. | $18.96 | 2024 | Cutaquig |
| Mylan Pharmaceuticals INC. | $16.92 | 2019 | |
| Hikma Pharmaceuticals USA | $13.79 | 2023 | Ryaltris |
| Merck Sharp & Dohme LLC | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amin Mery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.